retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 conducted in the USA Retatrutide Delivers 22.6% Weight Loss
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11


















